Kestra Medical Technologies (KMTS) Liabilities and Shareholders Equity (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $379.3 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 251.26% year-over-year to $379.3 million in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $1.2 billion (up 671.76% YoY) and the FY2025 annual result came in at $295.7 million, up 543.64% from the prior year.
• Liabilities and Shareholders Equity climbed to $379.3 million in Q1 2026 per KMTS's latest filing, from $246.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $379.3 million in Q1 2026 and bottomed at $45.9 million in Q2 2024.
• The 3-year median for Liabilities and Shareholders Equity is $256.5 million (2025), against an average of $223.7 million.
• The widest annual swing landed in 2025, when Liabilities and Shareholders Equity soared 543.64%; it then surged 251.26% in 2026.
• Tracing KMTS's Liabilities and Shareholders Equity over 3 years: stood at $45.9 million in 2024, then surged by 436.9% to $246.7 million in 2025, then surged by 53.77% to $379.3 million in 2026.
• Per Business Quant, the three latest KMTS Liabilities and Shareholders Equity figures stand at $379.3 million (Q1 2026), $246.7 million (Q4 2025), and $266.3 million (Q3 2025).

Peer Comparison